Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.49 |
| ▸ | PTGES | O14684 | 18/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12385442 | 0.81 | CHEK1 (0.39) | — | |
| SCHEMBL15767459 | 0.78 | CACNA1H (0.43) | CACNA1HPTGES | |
| SCHEMBL7485025 | 0.76 | CHEK1 (0.57) | CACNA1HPTGES | |
| SCHEMBL15767238 | 0.76 | SMN1; SMN2 (0.52) | CACNA1HPTGES | |
| SCHEMBL1917800 | 0.76 | PSMB8 (0.47) | CACNA1HPTGES | |
| SCHEMBL23581718 | 0.73 | PARP1 (0.61) | — | |
| SCHEMBL15767242 | 0.73 | PKN1 (0.57) | PTGES | |
| SCHEMBL13672554 | 0.73 | CHEK1 (0.41) | CACNA1H | |
| SCHEMBL11019853 | 0.72 | CNR2 (0.46) | CACNA1H | |
| SCHEMBL7475180 | 0.70 | PKN1 (0.51) | CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740730-B1 | DIBENZOOXEPIN DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-8969345-B2 | Dibenzooxepin derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140163008-A1 | DIBENZOOXEPIN DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-06-12 | — | — | US | disclosed |
| EP-2740730-A1 | DIBENZOOXEPIN DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2014-06-11 | — | — | EP | disclosed |
| US-20130131021-A1 | ANALOGUES OF CILOSTAZOL | CONCERT PHARMACEUTICALS INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131021-A1 | ANALOGUES OF CILOSTAZOL | PDE3A, PDE3B, PDE5A | CACNA1H 2080/4885PTGES 66/4885 |
| US-20140163008-A1 | DIBENZOOXEPIN DERIVATIVE | PPARA, PPARG, PPARD | CACNA1H 4271/4885PTGES 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.